Corvus Pharmaceuticals, Inc. (CRVS)
13.93
-0.46
(-3.20%)
USD |
NASDAQ |
Sep 08, 16:00
14.00
+0.07
(+0.50%)
Pre-Market: 09:15
Corvus Pharmaceuticals Shareholders Equity (Quarterly) : 225.33M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 225.33M |
| March 31, 2026 | 240.68M |
| December 31, 2025 | 61.20M |
| September 30, 2025 | 71.77M |
| June 30, 2025 | 80.23M |
| March 31, 2025 | 49.32M |
| December 31, 2024 | 32.57M |
| September 30, 2024 | 12.41M |
| June 30, 2024 | 51.23M |
| March 31, 2024 | 33.36M |
| December 31, 2023 | 38.68M |
| September 30, 2023 | 44.29M |
| June 30, 2023 | 49.48M |
| March 31, 2023 | 48.87M |
| December 31, 2022 | 56.12M |
| September 30, 2022 | 64.68M |
| June 30, 2022 | 80.39M |
| March 31, 2022 | 89.72M |
| December 31, 2021 | 97.16M |
| September 30, 2021 | 105.15M |
| June 30, 2021 | 96.40M |
| Date | Value |
|---|---|
| March 31, 2021 | 94.38M |
| December 31, 2020 | 72.15M |
| September 30, 2020 | 42.35M |
| June 30, 2020 | 50.84M |
| March 31, 2020 | 60.04M |
| December 31, 2019 | 71.11M |
| September 30, 2019 | 80.41M |
| June 30, 2019 | 89.65M |
| March 31, 2019 | 100.70M |
| December 31, 2018 | 110.34M |
| September 30, 2018 | 118.85M |
| June 30, 2018 | 127.40M |
| March 31, 2018 | 137.23M |
| December 31, 2017 | 84.84M |
| September 30, 2017 | 93.74M |
| June 30, 2017 | 104.78M |
| March 31, 2017 | 118.22M |
| December 31, 2016 | 132.80M |
| September 30, 2016 | 142.91M |
| June 30, 2016 | 151.97M |
| March 31, 2016 | 152.55M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| ACADIA Pharmaceuticals, Inc. | 1.307B |
| Alnylam Pharmaceuticals, Inc. | 1.354B |
| Anika Therapeutics, Inc. | 137.28M |
| Savara, Inc. | 143.66M |
| Vericel Corp. | 370.04M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 239.27M |
| Total Liabilities (Quarterly) | 13.95M |
| Debt to Equity Ratio | 0.0032 |
| Current Ratio | 16.16 |
| Net Debt Paydown Yield | 0.01% |